Capivasertib has anti-cancer potential for tumors with PIK3CA or PTEN gene alterations33 and is being tested in multiple in clinical trials (NCT02465060, NCT4439123, and NCT01226316) for hematological malignancies and solid tumors.34 Here, PIK3CA is linked to hematologic disorder.